Targets of TCR-T-cell therapy include glycoprotein gp100 (PMEL, melanoma), carcinoembryonic antigen (CEA, colorectal cancer), melanoma antigen recognized by T-cells 1 (MART-1, melanoma), melanoma-associated antigen 3 (MAGE-A3) (melanoma/multiple myeloma), and New York esophageal squamous cell carcinoma 1 (NY-ESO-1) (melanoma/synovial cell sarcoma) [37]. Here, MAGEA3 is linked to melanoma.